Clinical Trial Update: A Transition Study From Flolan® to Remodulin® in Patients With Pulmonary Arterial Hypertension [Phase 4]

View source ↗

Summary

This Phase 4 clinical trial update reports completion of a transition study from Flolan (epoprostenol) to Remodulin (treprostinil) in patients with pulmonary ar…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Arterial Hypertension
• Pulmonary Hypertension

Drugs mentioned

• FLOLAN (EPOPROSTENOL SODIUM)
• Remodulin (treprostinil)

Snippet

Sponsor: United Therapeutics | Conditions: Pulmonary Arterial Hypertension, Pulmonary Hypertension | Phase 4 | Status: COMPLETED